Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.

Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.

Abstract: A method for producing a solid electrolyte membrane (3) or an anode unit for a solid-state battery, in which method a powder mixture consisting of a solid electrolyte material and polytetrafluoroethylene is produced for the solid electrolyte membrane (3) and a powder mixture consisting of an electrode material, a solid electrolyte material, an electrically conductive conduction additive and polytetrafluoroethylene is produced for the anode unit, at least partially fibrillated polytetrafluoroethylene is formed by applying shear forces to the powder mixture, and the powder mixture is shaped into a flexible composite layer. The powder mixture has at most 1 wt. % polytetrafluoroethylene.

Abstract: A Histomonas meleagridis strain having at least one of the following attenuating features (a) an inactivation of a gene, wherein the gene has the sequence identified by SEQ ID NO: 1 or a sequence with at least 90% sequence identity thereto, (b) an inactivation of a gene, wherein the gene has the sequence identified by SEQ ID NO: 2 or a sequence with at least 90% sequence identity thereto, (c) a truncating mutation in the coding sequence of a gene, wherein the gene has the unmutated coding sequence identified by SEQ ID NO: 3 or an unmutated coding sequence with at least 95% sequence identity thereto, and (d) a truncating mutation in the coding sequence of a gene, wherein the gene has the unmutated coding sequence identified by SEQ ID NO: 4 or an unmutated coding sequence with at least 95% sequence identity thereto. An anti-histomonosis vaccine containing the strain.

Abstract: A system and method relate to encoding and decoding a contact matrix data structure. A system includes a processor and a computer-readable storage device storing a contact matrix data structure. The contact matrix data structure includes a header containing an interval of a contact matrix, a list of interval multipliers, a tile size, a list of chromosomes with a corresponding identifier and length, a list of sample identifiers, zero or more names of methods of normalization performed on the contact matrix tiles; zero or more bin payload having an interval multiplier; at least one parameter set; and at least one matrix payloads.

Abstract: The present invention generally relates to antibodies that bind to CSF1R and CD3, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease, in particular in the treatment of acute myeloid leukemia (AML).

Abstract: The invention provides a method of predicting the prognosis of a breast cancer patient by determining the expression level of p53 and GATA in a lymph node metastasis sample. The invention further encompasses pharmaceutical compositions, or methods of treating patients with a good or poor prognosis identified using the above methods, in addition to a kit, or system comprising the means to determine an expression level of p53 and/or GATA3 in a lymph node metastasis sample.

Abstract: Communication systems and methods in accordance with various embodiments of the invention utilize modulation on zeros. Carrier frequency offsets (CFO) can result in an unknown rotation of all zeros of a received signal's z-transform. Therefore, a binary MOCZ scheme (BMOCZ) can be utilized in which the modulated binary data is encoded using a cycling register code (e.g. CPC or ACPC), enabling receivers to determine cyclic shifts in the BMOCZ symbol resulting from a CFO. Receivers in accordance with several embodiments of the invention include decoders capable of decoding information bits from received discrete-time baseband signals by: estimating a timing offset for the received signal; determining a plurality of zeros of a z-transform of the received symbol; identifying zeros from the plurality of zeros that encode received bits by correcting fractional rotations resulting from the CFO; and decoding information bits based upon the received bits using a cycling register code.

Abstract: An electronic circuit having a semiconductor device is provided that includes a heterostructure, the heterostructure including a first layer of a compound semiconductor to which a second layer of a compound semiconductor adjoins in order to form a channel for a 2-dimensional electron gas (2DEG), wherein the 2-dimensional electron gas is not present. In aspects, an electronic circuit having a semiconductor device is provided that includes a III-V heterostructure, the III-V heterostructure including a first layer including GaN to which a second layer adjoins in order to form a channel for a 2-dimensional electron gas (2DEG), and having a purity such that the 2-dimensional electron gas is not present. It is therefore advantageous for the present electronic circuit to be enclosed such that, in operation, no light of wavelengths of less than 400 nm may reach the III-V heterostructure and free charge carriers may be generated by these wavelengths.

Abstract: The present invention pertains to a novel method for the generation of highly diverse RNA expressing vectors and vector libraries for use in targeted gene knock out, knock down and genome modification approaches. The invention pertains to a method for generating such higher order libraries without the need of classical cloning technologies. This is particularly useful for libraries based on large vectors wherein a sequence cannot be easily mutated with classical mutagenesis methods. The vectors and libraries generated according to the methods of the invention are in particular for RNA assisted silencing technologies such as RNA interference, and for targeted genome editing using the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system or similar RNA/DNA-encoded gene perturbation systems which use small guide RNAs to target the CRISPR complex to a specific genomic sequence. The invention provides also kits comprising the materials for performing the methods of the invention.

Abstract: The present invention relates to agents for use in the treatment of glioma, in particular astrocytoma WHO II° and III°, as well as IV° (glioblastoma), in a subject.

Abstract: The present disclosure refers to a method for decorrelating input signals from a physical identifier. In a system having one or more processors, the method comprises: providing input signals from a physical identifier: providing a decorrelation matrix; generating output signals, comprising decorrelating the input signals by applying the decorrelation matrix to the input signals; and providing the output signals at an output. The providing of the decorrelation matrix comprises: providing an initial matrix, the initial matrix being an orthogonal matrix; and determining the decorrelation matrix from the initial matrix by at least once selecting and applying at least one of a plurality of matrix extensions on the initial matrix, wherein each of the plurality of matrix extensions generates, from an input orthogonal matrix, a further orthogonal matrix with higher matrix dimension than the input orthogonal matrix. Furthermore, a system for decorrelating input signals from a physical identifier is provided.

Abstract: It is provided a process for modifying an aromatic polyether backbone for obtaining a modified polyether comprising the steps of: a) providing the at least one aromatic polyether to be modified in dissolved state in an inert organic solvent, b) adding at least one modification reagent, c) adding at least one catalyst, d) carrying out the process until a desired degree of functionalization of said aromatic polyether backbone is reached, e) recovery of the modified aromatic polyether.

Abstract: The present invention relates to adenovirus-associated virus comprising an influenza-derived neuraminidase transgene, used alone or together with an immune checkpoint inhibitor to treat a patient diagnosed with a solid cancer.

Abstract: The present invention relates to a compound comprising a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2) and TFGNSFAY (SEQ ID NO: 3), a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5) and ALWYSNHWV (SEQ ID NO: 6), or a variant of any one of said amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 6 having a different amino acid at one position, wherein said compound or variant is capable of binding to tumour-associated Mucin-1 (TA-MUC1).

Abstract: The present invention pertains to an improved chemical synthesis method for Ahp-cyclodepsipeptides which allows straight forward and easy synthesis of tailor-made Ahp-cyclodepsipeptides. The invention further provides Ahp-cyclodepsipeptides for use as HTRA protease inhibitors and their medical use.

Abstract: A composition for the transport of a dissolved active agent into hair follicles is provided that includes an active agent dissolved in a topical dispersion medium, and submicron particles. In one aspect, a pharmaceutical composition is provided for use in transporting a dissolved pharmacologically active therapeutical and/or prophylactic agent into hair follicles including a pharmacologically active therapeutic and/or prophylactic agent dissolved in a topical dispersion medium, and submicron particles. In embodiments, the active agent is not chemically coupled to the submicron particles. In a further aspect, the composition is a cosmetic composition including a cosmetically active agent, and the cosmetic composition can be used in a cosmetic method, in which the cosmetic composition is applied to an area of skin with hair follicles.

Abstract: The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit hCXCR4 and mCXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.

Abstract: The present invention relates to a method for generating and/or obtaining specific binding moieties against intrinsically disordered proteins (IDPs) and/or intrinsically disordered protein domains which tend to be immunologically inert and lack immunogenicity in animals, in particular in mammals. The present invention also relates to such specific binding moieties, in particular to antibodies and/or to antigen binding fragments thereof, specifically binding to structurally disordered and/or intrinsically disordered sequences, in particular to Pro/Ala-rich sequences (PAS). These binding moieties, antibodies, antigen binding fragments are first in class since they bind to/recognize disordered peptides or polypeptide fragments as also comprised in such “intrinsically disordered proteins”, in particular PAS polypeptides. The inventive binding moieties, antibodies, antigen binding fragments are, without being limiting, particularly useful in diagnostic settings as well as research tools.

Abstract: It is provided a method for activating dendritic cells in vitro, comprising the following steps: a) providing a substrate, wherein a surface of the substrate comprises at least one poly(glycidyl ether) derivative according to general formula (i); b) contacting the substrate with a dendritic cell in an isosmotic aqueous solution or buffer.